Kim So Mim, Lee Heera, Lee Eun-So
Department of Dermatology, Ajou University School of Medicine, Suwon, Korea.
Ann Dermatol. 2022 Aug;34(4):253-260. doi: 10.5021/ad.21.100.
Psoriasis is a multifactorial, chronic immunological disease, in which a specific allele HLA-Cw6 is associated with various clinical manifestations. However, information regarding this genetic factor in Korean patients with psoriasis remains limited.
We aimed to explore the differences in clinical patterns and treatment responsiveness, depending on the expression of HLA-Cw6, in Korean patients with psoriasis.
We divided patients into two groups, namely HLA-Cw6-positive and HLA-Cw6-negative, based on the HLA-Cw6 allelic analysis using the single specific primer-polymerase chain reaction method. All clinical information regarding these patients was collected in a retrospective manner. Next, we evaluated the levels of serum Th17-related cytokines in 34 patients diagnosed with psoriasis using a multiplex immunoassay. Finally, we performed immunohistochemical staining of interleukin (IL)-22 and IL-31, as these cytokines showed the maximum differential expression between the HLA-Cw6 positive and negative groups.
HLA-Cw6 positive and negative groups comprised of 13 and 21 patients, respectively. HLA-Cw6-positive group had more chance of having metabolic comorbidities (76.9% for HLA-Cw6-positive group; 28.6% for HLA-Cw6-negative group; =0.002). Also, HLA-Cw6-positive group showed significantly higher treatment response (38.5% in positive group showed Psoriasis Area and Severity Index 90% improvement compared to 4.8% in the negative group; =0.012). However, all Th17-related cytokines were not significantly different across the two groups. Furthermore, IL-22 and IL-31 immunohistochemical staining did not correlate with the serum cytokines levels.
HLA-Cw6 types can be associated with disease severity, comorbidities, and treatment responsiveness in Korean patients with psoriasis.
银屑病是一种多因素慢性免疫性疾病，其中特定等位基因HLA - Cw6与多种临床表现相关。然而，关于韩国银屑病患者中这一遗传因素的信息仍然有限。
我们旨在探讨韩国银屑病患者中，根据HLA - Cw6表达情况，临床模式和治疗反应性的差异。
我们使用单特异性引物 - 聚合酶链反应方法对HLA - Cw6进行等位基因分析，将患者分为两组，即HLA - Cw6阳性组和HLA - Cw6阴性组。以回顾性方式收集这些患者的所有临床信息。接下来，我们使用多重免疫测定法评估34例诊断为银屑病的患者血清中Th17相关细胞因子的水平。最后，我们对白介素（IL）-22和IL - 31进行免疫组织化学染色，因为这些细胞因子在HLA - Cw6阳性和阴性组之间表现出最大差异表达。
HLA - Cw6阳性组和阴性组分别由13例和21例患者组成。HLA - Cw6阳性组发生代谢合并症的几率更高（HLA - Cw6阳性组为76.9%；HLA - Cw6阴性组为28.6%；P = 0.002）。此外，HLA - Cw6阳性组显示出明显更高的治疗反应（阳性组中38.5%的患者银屑病面积和严重程度指数改善90%，而阴性组为4.8%；P = 0.012）。然而，两组间所有Th17相关细胞因子均无显著差异。此外，IL - 22和IL - 31免疫组织化学染色与血清细胞因子水平无关。
在韩国银屑病患者中，HLA - Cw6类型可能与疾病严重程度、合并症及治疗反应性相关。
